Luye Pharma Group Ltd.
LYPHF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $9,437 | $11,331 | $18,006 | $16,414 |
| - Cash | $4,937 | $3,239 | $2,324 | $2,438 |
| + Debt | $10,321 | $8,424 | $9,105 | $9,491 |
| Enterprise Value | $14,820 | $16,516 | $24,787 | $23,467 |
| Revenue | $6,061 | $6,143 | $5,982 | $5,200 |
| % Growth | -1.3% | 2.7% | 15% | – |
| Gross Profit | $4,044 | $4,204 | $4,141 | $3,397 |
| % Margin | 66.7% | 68.4% | 69.2% | 65.3% |
| EBITDA | $2,192 | $2,077 | $1,813 | $907 |
| % Margin | 36.2% | 33.8% | 30.3% | 17.4% |
| Net Income | $472 | $533 | $605 | -$145 |
| % Margin | 7.8% | 8.7% | 10.1% | -2.8% |
| EPS Diluted | 0.018 | 0.14 | 0.17 | -0.042 |
| % Growth | -87.5% | -17.6% | 504.8% | – |
| Operating Cash Flow | $168 | $1,595 | $1,654 | $182 |
| Capital Expenditures | -$1,708 | -$1,165 | -$1,164 | -$1,542 |
| Free Cash Flow | -$1,541 | $430 | $490 | -$1,359 |